By Colin Kenny, GP, Dromore
The authors of this study used the Swedish National Diabetes Register to analyse a total of 24,230 individuals with type 1 diabetes who did not have a history of cardiovascular disease (CVD). These individuals, of whom 18,843 were untreated and 5,387 were treated with lipid-lowering therapy (97% statins), were followed up for an average of 6 years. The authors estimated the association between lipid-lowering therapy and the risk of acute myocardial infarction, stroke, coronary heart disease, and cardiovascular and all-cause mortality.
After potential confounding risks were taken into consideration, lipid-lowering therapy was found to be associated with 22–44% reductions risk for various components of CVD and CVD-related death. The authors concluded that their analysis underlines the importance of primary prevention with lipid-lowering therapy to reduce risk of CVD in type 1 diabetes.
To access the full publication, click here (log-in or purchase required)
